What is Rein Therapeutics, Inc.'s earnings per share (EPS)?

Rein Therapeutics, Inc. (RNTX) reported diluted earnings per share of $-1.96 for fiscal year 2025. This represents a 44.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rein Therapeutics, Inc. Financials

RNTX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Rein Therapeutics, Inc. (RNTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RNTX FY2025 2026-04-27

Rein Therapeutics is still a cash-burn business funded mainly by equity issuance, and liquidity has tightened faster than leverage has risen.

Over the last three fiscal years, operating cash burn stayed close to -$20M annually even as net loss ballooned to -$49.9M, meaning reported losses became a poor proxy for actual cash use. With cash at $3.2M and the current ratio at 0.7x, near-term funding needs are now being set by liquidity rather than leverage.

The balance sheet is still lightly levered: liabilities were only $7.2M against equity of $16.9M, so the company has not extended runway by leaning on debt. Share count expansion from 4.9M to 27.6M shares across the last three fiscal years shows outside equity has been the main bridge for ongoing operating burn.

By the latest year, R&D and SG&A were both about $11M, versus a much more research-light cost mix earlier in the period. That reset helped narrow the accounting loss, but operating cash flow still ran at -$19.4M, so expense cuts have not yet changed the business from cash-consuming to cash-sustaining.

Financial Health Signals

Financial health score pending refresh

We are recalculating Rein Therapeutics, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-23.19

Rein Therapeutics, Inc. scores -23.19, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($85.4M) relative to total liabilities ($7.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Rein Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.39x

For every $1 of reported earnings, Rein Therapeutics, Inc. generates $0.39 in operating cash flow (-$19.4M OCF vs -$49.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Rein Therapeutics, Inc. generated $0 in revenue in fiscal year 2025.

EBITDA

-$50.6M

YoY+22.2%

Rein Therapeutics, Inc.'s EBITDA was -$50.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.2% from the prior year.

Net Income

-$49.9M

YoY+20.7%

Rein Therapeutics, Inc. reported -$49.9M in net income in fiscal year 2025. This represents an increase of 20.7% from the prior year.

EPS (Diluted)

$-1.96

YoY+44.2%

Rein Therapeutics, Inc. earned $-1.96 per diluted share (EPS) in fiscal year 2025. This represents an increase of 44.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.2M

YoY-75.0%

5Y CAGR-14.5%

10Y CAGR-1.6%

Rein Therapeutics, Inc. held $3.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

Rein Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

28M

YoY+27.2%

Rein Therapeutics, Inc. had 28M shares outstanding in fiscal year 2025. This represents an increase of 27.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-294.9%

YoY-179.3pp

5Y CAGR-70.2pp

Rein Therapeutics, Inc.'s ROE was -294.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 179.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$11.0M

YoY-22.6%

5Y CAGR-0.2%

10Y CAGR+3.5%

Rein Therapeutics, Inc. invested $11.0M in research and development in fiscal year 2025. This represents a decrease of 22.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RNTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.0M-22.6%	$14.2M+257.0%	$4.0M-77.8%	$18.0M+5.6%	$17.0M+52.3%	$11.2M
SG&A Expenses	$10.9M-21.4%	$13.9M+22.1%	$11.4M+17.3%	$9.7M+0.9%	$9.6M+2.9%	$9.3M
Operating Income	-$50.6M+22.2%	-$65.1M-300.0%	-$16.3M+41.1%	-$27.6M-3.9%	-$26.6M-29.8%	-$20.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$712K+53.9%	-$1.5M	$0	$0	$0	$0
Net Income	-$49.9M+20.7%	-$62.9M-300.6%	-$15.7M+42.6%	-$27.3M-4.5%	-$26.2M+4.3%	-$27.3M
EPS (Diluted)	$-1.96+44.2%	$-3.51	$-3.42+43.2%	$-6.02-2.2%	$-5.89	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
Cost of Revenue	$110K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.1M	N/A	$1.7M-60.8%	$4.3M+40.5%	$3.1M	N/A	$3.7M-0.5%	$3.7M
SG&A Expenses	$2.2M	N/A	$3.8M+47.8%	$2.6M+0.9%	$2.6M	N/A	$2.3M-55.7%	$5.3M
Operating Income	-$5.2M	N/A	-$5.5M+20.1%	-$6.9M-22.5%	-$5.6M	N/A	-$6.1M+32.8%	-$9.0M
Interest Expense	$11K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.8M	N/A	-$5.6M+18.2%	-$6.8M-24.0%	-$5.5M	N/A	-$5.8M+34.6%	-$8.9M
EPS (Diluted)	$-0.19	N/A	$-0.21+25.0%	$-0.28-12.0%	$-0.25	N/A	$-0.27+40.0%	$-0.45

RNTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$24.2M-61.2%	$62.2M-41.3%	$106.0M+381.7%	$22.0M-54.6%	$48.5M+196.7%	$16.3M
Current Assets	$4.3M-68.3%	$13.7M-25.2%	$18.3M-16.5%	$21.9M-54.6%	$48.2M+195.1%	$16.3M
Cash & Equivalents	$3.2M-75.0%	$12.9M-25.8%	$17.3M+233.8%	$5.2M+44.3%	$3.6M-48.9%	$7.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.3M0.0%	$6.3M0.0%	$6.3M	N/A	N/A	N/A
Total Liabilities	$7.2M-7.2%	$7.8M+1.1%	$7.7M+127.9%	$3.4M-26.1%	$4.6M+9.5%	$4.2M
Current Liabilities	$6.2M+7.5%	$5.7M+31.1%	$4.4M+29.6%	$3.4M-24.9%	$4.5M+13.8%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.9M-68.9%	$54.4M-44.7%	$98.3M+427.8%	$18.6M-57.6%	$43.9M+261.0%	$12.2M
Retained Earnings	-$401.3M-14.2%	-$351.4M-21.8%	-$288.5M-5.8%	-$272.8M-11.1%	-$245.5M-11.9%	-$219.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$26.3M+8.8%	$24.2M-55.0%	$53.7M-6.6%	$57.5M-0.3%	$57.6M-7.3%	$62.2M-40.3%	$104.2M-4.7%	$109.4M
Current Assets	$5.5M+26.1%	$4.3M-16.4%	$5.2M-21.6%	$6.6M-20.8%	$8.3M-39.0%	$13.7M-26.9%	$18.7M-19.3%	$23.2M
Cash & Equivalents	$4.4M+38.3%	$3.2M-20.6%	$4.0M-29.3%	$5.7M-23.0%	$7.4M-42.3%	$12.9M-27.1%	$17.7M-19.5%	$21.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M
Total Liabilities	$14.7M+103.0%	$7.2M-3.7%	$7.5M-20.6%	$9.5M+22.2%	$7.7M-0.6%	$7.8M-13.2%	$9.0M+7.2%	$8.4M
Current Liabilities	$13.6M+120.7%	$6.2M+7.6%	$5.7M-25.3%	$7.7M+28.7%	$6.0M+4.0%	$5.7M+1.6%	$5.7M+14.6%	$4.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.6M-31.5%	$16.9M-63.4%	$46.2M-3.8%	$48.0M-3.7%	$49.9M-8.3%	$54.4M-42.9%	$95.2M-5.7%	$101.0M
Retained Earnings	-$407.1M-1.5%	-$401.3M-8.7%	-$369.3M-1.5%	-$363.7M-1.9%	-$356.9M-1.6%	-$351.4M-13.2%	-$310.4M-1.9%	-$304.6M

RNTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$19.4M+13.1%	-$22.3M-12.5%	-$19.8M+20.3%	-$24.9M-4.7%	-$23.8M-16.0%	-$20.5M
Capital Expenditures	N/A	N/A	N/A	N/A	$157K+3040.0%	$5K
Free Cash Flow	N/A	N/A	N/A	N/A	-$23.9M-16.7%	-$20.5M
Investing Cash Flow	N/A	$0-100.0%	$16.2M-38.8%	$26.5M+173.7%	-$35.9M-660.2%	$6.4M
Financing Cash Flow	$9.8M-45.3%	$17.8M+12.8%	$15.8M	N/A	$55.7M+252.3%	$15.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.4M-6.3%	-$3.2M+9.2%	-$3.5M+44.7%	-$6.4M-3.9%	-$6.2M-28.3%	-$4.8M-26.0%	-$3.8M+54.5%	-$8.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Financing Cash Flow	$4.7M+93.5%	$2.4M+26.6%	$1.9M-59.7%	$4.7M+538.5%	$738K+73700.0%	$1K+100.2%	-$446K-102.4%	$18.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RNTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-294.9%-179.3pp	-115.6%-99.7pp	-16.0%+130.8pp	-146.8%-87.2pp	-59.6%+165.1pp	-224.7%
Return on Assets	-206.6%-105.4pp	-101.1%-86.3pp	-14.8%+109.4pp	-124.2%-70.2pp	-54.0%+113.3pp	-167.2%
Current Ratio	0.70-1.7	2.38-1.8	4.17-2.3	6.46-4.2	10.69+6.6	4.12
Debt-to-Equity	0.43+0.3	0.14+0.1	0.08-0.1	0.18+0.1	0.10-0.2	0.34
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-50.4%	N/A	-12.1%+2.1pp	-14.2%-3.2pp	-11.0%	N/A	-6.1%+2.7pp	-8.8%
Return on Assets	-22.2%	N/A	-10.4%+1.5pp	-11.9%-2.3pp	-9.6%	N/A	-5.6%+2.6pp	-8.2%
Current Ratio	0.40-0.3	0.70-0.2	0.90+0.0	0.86-0.5	1.39-1.0	2.38-0.9	3.30-1.4	4.69
Debt-to-Equity	1.27+0.8	0.43+0.3	0.16-0.0	0.20+0.0	0.16+0.0	0.14+0.0	0.09+0.0	0.08
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.70), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Akari Therapeutics Plc AKTX

$23.0M

Neuphoria Therapeutics Inc NEUP

$19.0M

BOUNDLESS BIO INC BOLD

$56.4M

Kezar Life Sciences KZR

$53.9M

Tenax Therapeutics Inc TENX

$485.9M

Frequently Asked Questions

What is Rein Therapeutics, Inc.'s annual revenue?

Rein Therapeutics, Inc. (RNTX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Rein Therapeutics, Inc. profitable?

No, Rein Therapeutics, Inc. (RNTX) reported a net income of -$49.9M in fiscal year 2025.

What is Rein Therapeutics, Inc.'s EBITDA?

Rein Therapeutics, Inc. (RNTX) had EBITDA of -$50.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rein Therapeutics, Inc.'s return on equity (ROE)?

Rein Therapeutics, Inc. (RNTX) has a return on equity of -294.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rein Therapeutics, Inc.'s operating cash flow?

Rein Therapeutics, Inc. (RNTX) generated -$19.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rein Therapeutics, Inc.'s total assets?

Rein Therapeutics, Inc. (RNTX) had $24.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Rein Therapeutics, Inc. spend on research and development?

Rein Therapeutics, Inc. (RNTX) invested $11.0M in research and development during fiscal year 2025.

How many shares does Rein Therapeutics, Inc. have outstanding?

Rein Therapeutics, Inc. (RNTX) had 28M shares outstanding as of fiscal year 2025.

What is Rein Therapeutics, Inc.'s current ratio?

Rein Therapeutics, Inc. (RNTX) had a current ratio of 0.70 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Rein Therapeutics, Inc.'s debt-to-equity ratio?

Rein Therapeutics, Inc. (RNTX) had a debt-to-equity ratio of 0.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rein Therapeutics, Inc.'s return on assets (ROA)?

Rein Therapeutics, Inc. (RNTX) had a return on assets of -206.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rein Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Rein Therapeutics, Inc. (RNTX) had $3.2M in cash against an annual operating cash burn of $19.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rein Therapeutics, Inc.'s Altman Z-Score?

Rein Therapeutics, Inc. (RNTX) has an Altman Z-Score of -23.19, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rein Therapeutics, Inc.'s Piotroski F-Score?

Rein Therapeutics, Inc. (RNTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rein Therapeutics, Inc.'s earnings high quality?

Rein Therapeutics, Inc. (RNTX) has an earnings quality ratio of 0.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.